{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T06:25:19Z","timestamp":1792650319797,"version":"4.5.0"},"reference-count":52,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82350128"],"award-info":[{"award-number":["82350128"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82303694"],"award-info":[{"award-number":["82303694"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004912","name":"Sichuan University","doi-asserted-by":"publisher","award":["ZYJC21003"],"award-info":[{"award-number":["ZYJC21003"]}],"id":[{"id":"10.13039\/501100004912","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002858","name":"China Postdoctoral Science Foundation","doi-asserted-by":"publisher","award":["2022M722274"],"award-info":[{"award-number":["2022M722274"]}],"id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","redjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Radiation Oncology*Biology*Physics"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.ijrobp.2025.04.011","type":"journal-article","created":{"date-parts":[[2025,4,17]],"date-time":"2025-04-17T19:21:23Z","timestamp":1744917683000},"page":"536-549","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Stimulator of Interferon Genes Agonist Synergistically Amplifies Programmed Cell Death Protein-1 Blockade and Radiation-Induced Systemic Antitumor Responses via Tumor Microenvironment Enrichment"],"prefix":"10.1016","volume":"123","author":[{"given":"Yue","family":"Zheng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pengfei","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuangsi","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guo","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ren","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zichong","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanghai","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linglu","family":"Yi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruizhan","family":"Tong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianxin","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuoran","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"You","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijrobp.2025.04.011_bib0001","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s12943-021-01489-2","article-title":"Combination strategies with PD-1\/PD-L1 blockade: Current advances and future directions","volume":"21","author":"Yi","year":"2022","journal-title":"Mol Cancer"},{"key":"10.1016\/j.ijrobp.2025.04.011_bib0002","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2023.216239","article-title":"Tackling the current dilemma of immunotherapy in extensive-stage small cell lung cancer: A promising strategy of combining with radiotherapy","volume":"565","author":"Kang","year":"2023","journal-title":"Cancer Lett"},{"key":"10.1016\/j.ijrobp.2025.04.011_bib0003","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1146\/annurev-immunol-070621-030155","article-title":"Resistance mechanisms to anti-PD cancer immunotherapy","volume":"40","author":"Vesely","year":"2022","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.ijrobp.2025.04.011_bib0004","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-000537","article-title":"Low-dose radiation treatment enhances systemic antitumor immune responses by overcoming the inhibitory stroma","volume":"8","author":"Barsoumian","year":"2020","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.ijrobp.2025.04.011_bib0005","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.ccr.2013.09.014","article-title":"Low-dose irradiation programs macrophage differentiation to an iNOS\u207a\/M1 phenotype that orchestrates effective T cell immunotherapy","volume":"24","author":"Klug","year":"2013","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ijrobp.2025.04.011_bib0006","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/j.ccr.2013.10.019","article-title":"A new twist on radiation oncology: Low-dose irradiation elicits immunostimulatory macrophages that unlock barriers to tumor immunotherapy","volume":"24","author":"De Palma","year":"2013","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ijrobp.2025.04.011_bib0007","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1002\/ijc.34801","article-title":"Low-dose radiation therapy mobilizes antitumor immunity: New findings and future perspectives","volume":"154","author":"Zhou","year":"2024","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ijrobp.2025.04.011_bib0008","doi-asserted-by":"crossref","first-page":"4098","DOI":"10.1158\/1078-0432.CCR-23-0315","article-title":"Safety and tolerability of low-dose radiation and stereotactic body radiotherapy + sintilimab for treatment-na\u00efve stage IV PD-L1+ non-small cell lung cancer patients","volume":"29","author":"Zhou","year":"2023","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ijrobp.2025.04.011_bib0009","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1158\/2159-8290.CD-21-0003","article-title":"Low-dose radiotherapy reverses tumor immune desertification and resistance to immunotherapy","volume":"12","author":"Herrera","year":"2022","journal-title":"Cancer Discov"},{"key":"10.1016\/j.ijrobp.2025.04.011_bib0010","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1016\/j.medj.2024.06.002","article-title":"Preclinical study and phase II trial of adapting low-dose radiotherapy to immunotherapy in small cell lung cancer","volume":"5","author":"Wang","year":"2024","journal-title":"Med"},{"key":"10.1016\/j.ijrobp.2025.04.011_bib0011","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1038\/s43018-022-00468-w","article-title":"The cGAS-STING pathway and cancer","volume":"3","author":"Samson","year":"2022","journal-title":"Nat Cancer"},{"key":"10.1016\/j.ijrobp.2025.04.011_bib0012","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1158\/2159-8290.CD-19-0761","article-title":"The cytosolic DNA-sensing cGAS-STING pathway in cancer","volume":"10","author":"Kwon","year":"2020","journal-title":"Cancer Discov"},{"key":"10.1016\/j.ijrobp.2025.04.011_bib0013","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1056\/NEJMcibr2410049","article-title":"How DNA sensing drives inflammation","volume":"391","author":"Vance","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijrobp.2025.04.011_bib0014","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/s41568-020-0246-1","article-title":"Inflammatory microenvironment remodelling by tumour cells after radiotherapy","volume":"20","author":"McLaughlin","year":"2020","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.ijrobp.2025.04.011_bib0015","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.molcel.2020.07.026","article-title":"DNA damage and cancer immunotherapy: A STING in the tale","volume":"80","author":"Reisl\u00e4nder","year":"2020","journal-title":"Mol Cell"},{"key":"10.1016\/j.ijrobp.2025.04.011_bib0016","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1186\/s13045-020-00916-z","article-title":"cGAS-STING, an important pathway in cancer immunotherapy","volume":"13","author":"Jiang","year":"2020","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.ijrobp.2025.04.011_bib0017","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1038\/s41586-018-0705-y","article-title":"Design of amidobenzimidazole STING receptor agonists with systemic activity","volume":"564","author":"Ramanjulu","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.ijrobp.2025.04.011_bib0018","doi-asserted-by":"crossref","first-page":"eaba6098","DOI":"10.1126\/science.aba6098","article-title":"An orally available non-nucleotide STING agonist with antitumor activity","volume":"369","author":"Pan","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.ijrobp.2025.04.011_bib0019","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1038\/s41467-023-37328-9","article-title":"STING agonist-loaded, CD47\/PD-L1-targeting nanoparticles potentiate antitumor immunity and radiotherapy for glioblastoma","volume":"14","author":"Zhang","year":"2023","journal-title":"Nat Commun"},{"key":"10.1016\/j.ijrobp.2025.04.011_bib0020","doi-asserted-by":"crossref","first-page":"3022","DOI":"10.1038\/s41467-022-30568-1","article-title":"STING agonism reprograms tumor-associated macrophages and overcomes resistance to PARP inhibition in BRCA1-deficient models of breast cancer","volume":"13","author":"Wang","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.ijrobp.2025.04.011_bib0021","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1186\/s13045-018-0647-8","article-title":"Abscopal effect of radiotherapy combined with immune checkpoint inhibitors","volume":"11","author":"Liu","year":"2018","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.ijrobp.2025.04.011_bib0022","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1056\/NEJMc1203984","article-title":"Abscopal effect in a patient with melanoma","volume":"366","author":"Hiniker","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijrobp.2025.04.011_bib0023","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1038\/s43018-022-00456-0","article-title":"Radiotherapy in combination with CD47 blockade elicits a macrophage-mediated abscopal effect","volume":"3","author":"Nishiga","year":"2022","journal-title":"Nat Cancer"},{"key":"10.1016\/j.ijrobp.2025.04.011_bib0024","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-008515","article-title":"Colorectal cancer-specific IFN\u03b2 delivery overcomes dysfunctional dsRNA-mediated type I interferon signaling to increase the abscopal effect of radiotherapy","volume":"12","author":"Huang","year":"2024","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.ijrobp.2025.04.011_bib0025","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1002\/cac2.12348","article-title":"Pivotal roles of tumor-draining lymph nodes in the abscopal effects from combined immunotherapy and radiotherapy","volume":"42","author":"Liu","year":"2022","journal-title":"Cancer Commun (Lond)"},{"key":"10.1016\/j.ijrobp.2025.04.011_bib0026","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-006235","article-title":"Adding liposomal doxorubicin enhances the abscopal effect induced by radiation\/\u03b1PD1 therapy depending on tumor cell mitochondrial DNA and cGAS\/STING","volume":"11","author":"Wang","year":"2023","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.ijrobp.2025.04.011_bib0027","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2023.216507","article-title":"Olaparib enhances radiation-induced systemic anti-tumor effects via activating STING-chemokine signaling in hepatocellular carcinoma","volume":"582","author":"Chen","year":"2024","journal-title":"Cancer Lett"},{"key":"10.1016\/j.ijrobp.2025.04.011_bib0028","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1038\/s43018-022-00361-6","article-title":"KMT2C deficiency promotes small cell lung cancer metastasis through DNMT3A-mediated epigenetic reprogramming","volume":"3","author":"Na","year":"2022","journal-title":"Nat Cancer"},{"key":"10.1016\/j.ijrobp.2025.04.011_bib0029","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.ijrobp.2020.05.002","article-title":"Effect of low-dose radiation therapy on abscopal responses to hypofractionated radiation therapy and anti-PD1 in mice and patients with non-small cell lung cancer","volume":"108","author":"Yin","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2025.04.011_bib0030","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1136\/gutjnl-2024-332371","article-title":"CD64+ fibroblast-targeted vilanterol and a STING agonist augment CLDN18.2 BiTEs efficacy against pancreatic cancer by reducing desmoplasia and enriching stem-like CD8+ T cells","volume":"73","author":"Zhou","year":"2024","journal-title":"Gut"},{"key":"10.1016\/j.ijrobp.2025.04.011_bib0031","doi-asserted-by":"crossref","first-page":"eabn6612","DOI":"10.1126\/sciimmunol.abn6612","article-title":"Selective STING stimulation in dendritic cells primes antitumor T cell responses","volume":"8","author":"Jneid","year":"2023","journal-title":"Sci Immunol"},{"key":"10.1016\/j.ijrobp.2025.04.011_bib0032","doi-asserted-by":"crossref","first-page":"eadj3945","DOI":"10.1126\/sciimmunol.adj3945","article-title":"STING licensing of type I dendritic cells potentiates antitumor immunity","volume":"9","author":"Wang","year":"2024","journal-title":"Sci Immunol"},{"key":"10.1016\/j.ijrobp.2025.04.011_bib0033","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1186\/s13045-022-01363-8","article-title":"Combination of oral STING agonist MSA-2 and anti-TGF-\u03b2\/PD-L1 bispecific antibody YM101: A novel immune cocktail therapy for non-inflamed tumors","volume":"15","author":"Yi","year":"2022","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.ijrobp.2025.04.011_bib0034","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-006481","article-title":"Macrophage STING signaling promotes NK cell to suppress colorectal cancer liver metastasis via 4-1BBL\/4-1BB co-stimulation","volume":"11","author":"Sun","year":"2023","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.ijrobp.2025.04.011_bib0035","doi-asserted-by":"crossref","DOI":"10.1172\/JCI166031","article-title":"Glycolysis drives STING signaling to facilitate dendritic cell antitumor function","volume":"133","author":"Hu","year":"2023","journal-title":"J Clin Invest"},{"key":"10.1016\/j.ijrobp.2025.04.011_bib0036","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2111003119","article-title":"STING activation promotes robust immune response and NK cell-mediated tumor regression in glioblastoma models","volume":"119","author":"Berger","year":"2022","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.ijrobp.2025.04.011_bib0037","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.ccell.2023.12.005","article-title":"Interferon-stimulated neutrophils as a predictor of immunotherapy response","volume":"42","author":"Benguigui","year":"2024","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ijrobp.2025.04.011_bib0038","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001906","article-title":"STING agonist-based treatment promotes vascular normalization and tertiary lymphoid structure formation in the therapeutic melanoma microenvironment","volume":"9","author":"Chelvanambi","year":"2021","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.ijrobp.2025.04.011_bib0039","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/s41467-023-43743-9","article-title":"TET2-mediated tumor cGAS triggers endothelial STING activation to regulate vasculature remodeling and anti-tumor immunity in liver cancer","volume":"15","author":"Lv","year":"2024","journal-title":"Nat Commun"},{"key":"10.1016\/j.ijrobp.2025.04.011_bib0040","doi-asserted-by":"crossref","first-page":"eadd1153","DOI":"10.1126\/sciimmunol.add1153","article-title":"STING-activating nanoparticles normalize the vascular-immune interface to potentiate cancer immunotherapy","volume":"8","author":"Wang-Bishop","year":"2023","journal-title":"Sci Immunol"},{"key":"10.1016\/j.ijrobp.2025.04.011_bib0041","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1016\/S0140-6736(19)32222-6","article-title":"Durvalumab plus platinum\u2013etoposide versus platinum\u2013etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): A randomised, controlled, open-label, phase 3 trial","volume":"394","author":"Paz-Ares","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.ijrobp.2025.04.011_bib0042","doi-asserted-by":"crossref","first-page":"2369","DOI":"10.1200\/JCO.20.00793","article-title":"Pembrolizumab or placebo plus etoposide and platinum as first-line therapy for extensive-stage small-cell lung cancer: Randomized, double-blind, phase III KEYNOTE-604 study","volume":"38","author":"Rudin","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2025.04.011_bib0043","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/S1470-2045(22)00224-8","article-title":"Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): A multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"23","author":"Wang","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ijrobp.2025.04.011_bib0044","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1186\/s12943-020-01250-1","article-title":"Comprehensive elaboration of the cGAS-STING signaling axis in cancer development and immunotherapy","volume":"19","author":"Zheng","year":"2020","journal-title":"Mol Cancer"},{"key":"10.1016\/j.ijrobp.2025.04.011_bib0045","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.tcb.2022.06.010","article-title":"Targeting STING to promote antitumor immunity","volume":"33","author":"Chin","year":"2023","journal-title":"Trends Cell Biol"},{"issue":"suppl 4","key":"10.1016\/j.ijrobp.2025.04.011_bib0046","doi-asserted-by":"crossref","first-page":"S683","DOI":"10.1016\/j.annonc.2020.08.1087","article-title":"972TiP Phase II study of intratumoral MK-1454 plus pembrolizumab compared with pembrolizumab monotherapy as first-line treatment for metastatic or unresectable, recurrent head and neck squamous cell carcinoma","volume":"31","author":"Harrington","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ijrobp.2025.04.011_bib0047","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1158\/1078-0432.CCR-22-2235","article-title":"Combination of the STING agonist MIW815 (ADU-S100) and PD-1 inhibitor spartalizumab in advanced\/metastatic solid tumors or lymphomas: An open-label, multicenter, phase Ib study","volume":"29","author":"Meric-Bernstam","year":"2023","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ijrobp.2025.04.011_bib0048","doi-asserted-by":"crossref","first-page":"5977","DOI":"10.1021\/acs.chemrev.1c00750","article-title":"Chemical and biomolecular strategies for STING pathway activation in cancer immunotherapy","volume":"122","author":"Garland","year":"2022","journal-title":"Chem Rev"},{"key":"10.1016\/j.ijrobp.2025.04.011_bib0049","doi-asserted-by":"crossref","first-page":"2933","DOI":"10.1021\/acs.accounts.3c00394","article-title":"Engineering and delivery of cGAS-STING immunomodulators for the immunotherapy of cancer and autoimmune diseases","volume":"56","author":"Zhou","year":"2023","journal-title":"Acc Chem Res"},{"key":"10.1016\/j.ijrobp.2025.04.011_bib0050","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s13045-019-0721-x","article-title":"Activating cGAS-STING pathway for the optimal effect of cancer immunotherapy","volume":"12","author":"Li","year":"2019","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.ijrobp.2025.04.011_bib0051","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1126\/science.aaa4967","article-title":"Adoptive cell transfer as personalized immunotherapy for human cancer","volume":"348","author":"Rosenberg","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.ijrobp.2025.04.011_bib0052","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1038\/s41392-022-01136-2","article-title":"Therapeutic targets and biomarkers of tumor immunotherapy: Response versus non-response","volume":"7","author":"Wang","year":"2022","journal-title":"Signal Transduct Target Ther"}],"container-title":["International Journal of Radiation Oncology*Biology*Physics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301625003736?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301625003736?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T14:50:23Z","timestamp":1777560623000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0360301625003736"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":52,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["S0360301625003736"],"URL":"https:\/\/doi.org\/10.1016\/j.ijrobp.2025.04.011","relation":{},"ISSN":["0360-3016"],"issn-type":[{"value":"0360-3016","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Stimulator of Interferon Genes Agonist Synergistically Amplifies Programmed Cell Death Protein-1 Blockade and Radiation-Induced Systemic Antitumor Responses via Tumor Microenvironment Enrichment","name":"articletitle","label":"Article Title"},{"value":"International Journal of Radiation Oncology*Biology*Physics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijrobp.2025.04.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}